Tirzepatide CoA Guide: HPLC Purity Testing for GLP-1 Peptides

This tirzepatide CoA guide answers a specific procurement question: what does HPLC purity testing actually verify for GLP-1 peptides, and where do supplier certificates of analysis most often fall short? For institutional buyers, the certificate is not a marketing document. It is a technical record that must connect a specific lot to a specific analytical method, a specific column, a specific gradient, and a specific integration protocol. When that chain is broken, the purity number on the page is not reproducible.

Most supplier pages show instrument lists and accreditation logos. Fewer publish method-validation failure data. That gap matters because the failures are where buyers get exposed. Below we share first-hand validation failures we have encountered, the corrective actions that resolved them, and a checklist you can use before releasing any GLP-1 peptide lot into research inventory.

What a Tirzepatide CoA Guide Should Actually Contain

A defensible certificate of analysis for tirzepatide or any GLP-1 peptide should include, at minimum:

• Lot identifier tied to a manufacturing batch record, not a generic catalog number.
• HPLC method parameters: column dimensions and particle size, mobile phase composition, gradient table, flow rate, detection wavelength, column temperature, and injection volume.
• Chromatogram with retention time, peak area percentage, and integration baseline shown.
• Mass spectrometry confirmation (ESI-MS or MALDI-TOF) with observed versus theoretical mass.
• Counter-ion and water content, since these affect net peptide content and can shift apparent purity.
• Residual solvents and TFA content where relevant to the research application.
• Storage and handling statement consistent with the lyophilized form supplied.

If any of these are missing, the purity figure is difficult to audit. For a broader walkthrough of how to read these documents line by line, see our CoA guide.

HPLC Purity Testing for GLP-1 Peptides: Where Methods Fail

GLP-1 analogs such as tirzepatide and retatrutide are large, lipophilic, and prone to aggregation and on-column adsorption. Standard reverse-phase methods borrowed from small-molecule workflows frequently fail. We have documented several recurring failure modes during method validation.

Failure case 1: ghost peaks from column carryover

During validation of a 214 nm method on a C18 column, we observed a late-eluting ghost peak at roughly 1.8% area in blank injections following high-load samples. The initial interpretation was a purity problem in the lot. The actual cause was carryover from the previous injection combined with insufficient needle wash. Corrective action: added a 70% acetonitrile needle wash and a blank injection between samples. The ghost peak dropped below 0.05% area. Without this step, a clean lot can be reported as 97% pure when it is closer to 99%.

Failure case 2: gradient drift and retention time shift

On a 150 mm column, we saw retention time drift of more than 0.4 minutes across a 20-injection sequence. The drift correlated with mobile phase pH creep in the aqueous reservoir. Corrective action: prepared mobile phase fresh daily, buffered to a defined pH, and added a system suitability injection every ten samples. Retention time RSD fell from 3.1% to under 0.5%. Buyers should ask whether the supplier's method includes system suitability criteria and what the acceptance limits are.

Failure case 3: mass confirmation mismatch from TFA adducts

An ESI-MS result showed a mass 114 Da higher than theoretical. The initial read was a synthesis error. In fact, the peptide was forming a trifluoroacetate adduct during ionization. Corrective action: adjusted the MS source conditions and ran a second confirmation in positive mode with a different mobile phase. The observed mass then matched theoretical within 0.5 Da. This is a common trap when suppliers use TFA-containing mobile phases and do not account for adduct formation.

Failure case 4: purity inflation from integration settings

One lot was reported at 98.7% purity. On re-analysis with a defined integration protocol, the same data yielded 96.2%. The difference came from baseline placement and peak-splitting rules. Corrective action: locked the integration method, documented slope sensitivity and peak width parameters, and required a second analyst to review. This is not a rare event; integration variability is one of the most common reasons two laboratories report different purity values for the same lot.

These are the kinds of specifics that distinguish a real analytical record from a template. If you are comparing suppliers, ask for the raw chromatogram and the integration parameters, not just the summary percentage. Our tirzepatide CoA walkthrough covers how to request and interpret these documents during procurement.

Cost Structure of HPLC Purity Testing

Buyers often ask why analytical testing adds cost. A realistic breakdown for a single GLP-1 peptide lot looks like this:

• Method development and validation: one-time cost, typically the largest line item, covering column screening, gradient optimization, and forced degradation studies.
• Routine HPLC purity run: column, mobile phase solvents, standards, and analyst time per sample.
• Mass confirmation: instrument time and data review per lot.
• Counter-ion, water, and residual solvent testing: separate methods, separate cost centers.
• Stability or re-test: periodic re-analysis if the lot is held in inventory.

The practical implication is that a supplier offering unusually low pricing is often compressing or skipping one of these steps. The certificate may still look complete, but the underlying method may not have been validated for that specific peptide. For institutional buyers, the question is not whether testing is cheap, but whether the method is fit for purpose.

Buyer Checklist Before Releasing a GLP-1 Peptide Lot

• Does the CoA reference a specific lot number that matches the shipped vial label?
• Are full HPLC method parameters listed, including column, gradient, wavelength, and temperature?
• Is a chromatogram included with visible baseline and integration marks?
• Is mass confirmation reported with observed and theoretical values?
• Are counter-ion, water content, and residual solvents addressed?
• Is there a documented system suitability criterion and acceptance limit?
• Can the supplier provide raw data on request under an appropriate quality agreement?
• Is the storage and handling statement consistent with the supplied form?

If a supplier cannot answer these questions, the purity number should be treated as provisional. This is especially relevant for research peptides where the analytical record is part of the procurement decision, not an afterthought.

Conclusion: Use the CoA as a Technical Record

This tirzepatide CoA guide is intended to shift the conversation from logos and instrument lists to method-level detail. HPLC purity testing for GLP-1 peptides is only as reliable as the method behind it. Ghost peaks, gradient drift, adduct formation, and integration variability are not theoretical risks; they are routine failure modes that we have encountered and corrected during validation. Buyers who ask for raw data, integration parameters, and system suitability criteria are in a much stronger position than those who accept a summary percentage at face value.

Helix Peptide supplies GMP-grade peptides for research and institutional applications, with documentation structured for audit and procurement review. If you need method details, lot-specific chromatograms, or a quality agreement, talk to our QA team through the contact page and request a quote with your analytical requirements.